Prof. Robert N. MULLER, UMONS
Robert N. Muller was born in 1948 and studied at the University of Mons-Hainaut (UMH), Belgium, from which he was graduated with a Lic. Sci. Degree in chemistry in 1969. He obtained his PhD in 1974 from the same University where he was successively appointed Assistant, Lecturer and full Professor. He is currently head of the Department of General, Organic and Biomedical Chemistry and, since October 2005, Dean of the Faculty of Medicine and Pharmacy of the University of Mons. He did post-doctoral studies in Magnetic Resonance Imaging in Paul C. Lauterbur’s* research group at the State University of New York at Stony Brook in 1981-82, collaborated with Drs Seymour Koenig in the domain of fast field cycling relaxometry and was on a sabbatical leave at the Center for Magnetic Resonance (CERM), Florence, Italy with Professors Ivano Bertini and Claudio Luchinat in 2002-2003. Co-founder of the European Workshop on Nuclear Magnetic Resonance in Medicine; Vice-Chairman of the European Magnetic Resonance Forum Foundation, 1991-present; President of the European Society for Magnetic Resonance in Medicine and Biology, 1987-1988; President of the GRAMM (Groupe de Recherche sur les Applications du Magnétisme en Médecine), 1998-2000; Vice-Chairman of the COST D18 Action, 2003; Founding member of the European Society for Molecular Imaging (ESMI); Editor in chief of the new journal Contrast Media and Molecular Imaging (Wiley) and Member of the editorial boards of Magnetic Resonance Materials MAGMA (Springer) and Investigative Radiology (Lipincott). He has produced around 200 publications and contributed to 6 books mainly in NMR relaxometry, spectroscopy and imaging in the context of the development and applications of contrast agents for Molecular Imaging. Relevant awards: Outstanding teacher award of the International Society for Magnetic Resonance in Medicine ISMRM (2005) Outstanding teacher award of the International Society for Magnetic Resonance in Medicine ISMRM (2007) Contrast Media Research Award (2009)
Fellow of the European Society for magnetic Resonance in Medicine and Biology (2010)
*2003 Nobel Prize in Medicine or Physiology
Dr Sébastien BOUTRY, Ph. D.
Sébastien Boutry was born in 1978 and studied at the University of Mons (UMons) from which he graduated with a M.Sc. Degree (Biology) in 2001. He became a researcher in the nuclear magnetic resonance (NMR) and molecular imaging laboratory of Prof. Robert N. Muller (UMons). Using the magnetic resonance imaging (MRI) technique as a tool for biological studies, he first focused on MRI contrast agents (gadolinium-based as well as iron oxide-based) specific for molecular markers of inflammation, developed in the laboratory (six papers were published). He obtained his Ph.D. in Biology in 2007. During his thesis, he performed and published several studies on the magnetic labelling of cells with iron oxide-based nanoparticular MRI contrast agents. He also attempted to use specifically vectorized nanoparticles as tools for the tracing of brain neurons in the context of an Interuniversity Attraction Poles program. This specific cellular targeting aspect was also approached in a work he started as a “FNRS – Télévie” scientific collaborator in 2006, aiming at the development of a specifically targeted contrast agent which might allow for the MRI monitoring of the efficiency of pro-apoptotic drugs used for anti-cancer therapies. In 2008, he became a research collaborator in the Center for Microscopy and Molecular Imaging (CMMI). He is developing biological applications of NMR (MRI and MR spectroscopy), but also other techniques of molecular imaging such as optical imaging and nuclear medicine.
Mathieu ROCH, B. Electr.
Mathieu Roch was born in 1983. He studied at the “Roi Baudoin” High School (Mons) from which he graduated with a B.Sc. Degree (Electronics) in 2004. For 4 years, he worked in the electronic development of traffic radars for the Belgian society SIRIEN. In 2009, he joined the Center for Microscopy and Molecular Imaging (CMMI) as a technical collaborator responsible for the maintenance of NMR equipments and for the running of MRI and optical imaging experiments.
Lionel LARBANOIX, Dr Sc
Lionel Larbanoix: born in August, 1982 in Uccle (Belgium), he obtained his Master degree in biology in 2005 from the University of Mons, Belgium. He obtained his Ph.D. in Biomedical Sciences in 2010 from the same university. His Ph.D. thesis was focused on the magnetic resonance imaging (MRI) of Alzheimer’s disease. He screened peptide libraries by using the phage display technology in order to find specific ligands of amyloid deposits. These ligands were then grafted on MR contrast agents to allow in vivo visualisation of amyloid plaques (results published in Neurobiology of Aging in 2008). He worked for two years in the DIAPATH unit within The Center for Microscopy and Molecular Imaging (CMMI). His activity was focused on the development of immunohistochemistry protocols and on the identification, characterization and validation of protein biomarkers. He is now a collaborator in the MRI and Optical Imaging units within the CMMI. His activity is focused on the development of biological applications of optical imaging and MRI.
Magnetic Resonance Imaging
9.4T Bruker Biospec (partially acquired with a grant from the Fund for Scientific Research FRS/FNRS)
1. S. Laurent, C. Henoumont, L. Vander Elst, R.N. Muller, Current Developments in contrast agents: Synthesis and Physico-Chemical Characterisation of Paramagnetic Contrast Agents for MRI, Eur. J. Inorg. Chem, 12, 1889-1915 (2012)
2. C. Henoumont, S. Laurent, R.N. Muller, L. Vander Elst, “Effect of Non-enzymatic Glycosylation on the MRI Contrast Agent Binding to Human Serum Albumin », J. Med Chem, accepté (2012)
3. Burtea C, Ballet S, Laurent S, Rousseaux O, Dencausse A, Gonzalez W, Port M, Corot C, Elst LV, Muller RN, Development of a Magnetic Resonance Imaging Protocol for the Characterization of Atherosclerotic Plaque by Using Vascular Cell Adhesion Molecule-1 and Apoptosis-Targeted Ultrasmall Superparamagnetic Iron Oxide Derivatives. Arterioscler Thromb Vasc Biol. accepté (2012)
4. Magnetic resonance imaging tracking of stem cells in vivo using iron oxide nanoparticles as a tool for the advancement of clinical regenerative medicine. Mahmoudi M, Hosseinkhani H, Hosseinkhani M, Boutry S, Simchi A, Journeay WS, Subramani K, Laurent S, Chem Rev. 111(2):253-280 (2011)
5. Early assessment of the degree of tumor response to irradiation by using MRI and phosphatidyserine-targeted USPIO particles”, K.A. Radermacher, S. Laurent, J. Magat, C. Bouzin, S. Boutry, I. Mahieu, L. Vander Elst, V.Gregoire, O. Feron, R.N. Muller, B.F. Jordan, B. Gallez, submitted
6. Multi-modal Assessment of Early Tumor Response to Chemotherapy: Comparison between Diffusion-Weighted MRI, 1H-MR Spectroscopy of Choline and USPIO Particles Targeted at Cell Death, K.A. Radermacher, J. Magat, C. Bouzin, S. Laurent, T. Dresselaers, U. Himmelreich, S. Boutry, I. Mahieu, L. Vander Elst, O. Feron, R. Muller, B.F. Jordan, B. Gallez.Article first published online: 23 Aug 2011
7. The Gd3+ complex of a conjugate of inulin and 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic acid mono(p-isothiocyanatoanilide), a potential kinetically stable blood-pool contrast agent for MRI, L. Granato, S. Laurent, L. Vander Elst, K. Djanashvili, J.A. Peters, R.N. Muller, Accepted for publication in Contratst Media Mol Imaging
8. Peptidic targeting of phosphatidylserine for the MRI detection of apoptosis in atherosclerotic plaques, C. Burtea, S. Laurent, E. Lancelot, S. Ballet, O. Murariu, O. Rousseaux, M. Port, L. Vander Elst, C. Corot, R.N. Muller, Mol Pharm. 6(6) : 1903-1919 (2009).
9. In vivo detection of inflammation using pegylated iron oxide particles targeted at E-selectin: a multimodal approach using MR imaging and EPR spectroscopy, K.A. Radermacher, N. Beghein, S. Boutry, S. Laurent, L. Vander Elst, R.N. Muller, B.F. Jordan, B. Gallez, Invest Radiol. 44(7):398-404 (2009)
10. Potential amyloid plaque-specific peptides for the diagnosis of Alzheimer’s disease L. Larbanoix, C. Burtea, S. Laurent, F. Van Leuven, G. Toubeau, L. Vander Elst, R.N. Muller, Neurobiol Aging. (2008) doi:10.1016/j.Neurobiol Aging. 31(10):1679-1689 (2010)
11. Magnetic labeling of non-phagocytic adherent cells with iron oxide nanoparticles: a comprehensive study, S. Boutry, S. Brunin, I. Mahieu, S. Laurent, L. Vander Elst, R.N. Muller, Contrast Media Mol Imaging. 3(6) 223-232 (2008).
12. Magnetic resonance imaging of inflammation with a specific selectin-targeted contrast agent, S. Boutry, C. Burtea, S. Laurent, G. Toubeau, L. Vander Elst, R.N. Muller, Magn Reson Med. 53(4):800-807 (2005).
- Magnetic resonance imaging and spectroscopy with a Biospec 94/20 system from Bruker. MRI allows for anatomical, dynamic and molecular applications of imaging, in 2D or 3D.
- Experiments are performed mainly on mice and rats.
- Other samples or organisms can be imaged (size has to be comparable to that of above-mentionned rodents).
- Systems for anesthetizing (isoflurane), warming and monitoring the animal are available.
- Contrast agents can be injected without modifying the animal position.
Magnetic Resonance Imaging (MRI) is based on the magnetic resonance principle, which occurs due to the tendency of an atom’s magnetic moment to align when placed in a magnetic field. Nowadays, this technique is not only considered to be one of the best for clinical radiology, but it is also largely used in scientific research because of the detailed and thorough information it can generate. Images can be obtained in vivo with very high spatial and temporal resolution.
Their quality and information content can be increased by the administration of specific contrast agents that will allow, for instance, a more effective detection of tumours or metastases. MRI can also be used in other biomedical applications, such as angiography (imaging of blood vessels), functional imaging (e.g. brain activation territories), cellular and molecular imaging and spectroscopy (simultaneous imaging and biochemical analysis of specific molecules or particular cell types).
The development of specific tracers (contrast agents) is carried out in collaboration with the Department of General, Organic and Biomedical Chemistry of the University of Mons (http://portail.umons.ac.be/fr/universite/facultes/fmp/services/service1/pages/default.aspx)
See the poster: POSTER_CMMI_-_MRI.pdf
See the video: http://www.eyecone.com/clients/LabInsight/ULB-IRM-IO/